BYSI - BeyondSpring rises 18% on positive data from trial of plinabulin to prevent docetaxel-induced neutropenia in NSCLC patients

• BeyondSpring ( NASDAQ: BYSI ) is trading ~18% higher after the company announced positive data from trial of lead asset, plinabulin, to prevent docetaxel-induced neutropenia in non-small cell lung cancer (NSCLC) patients.
• The analyses showed the efficacy of plinabulin as a monotherapy in reducing the mean duration of severe neutropenia with a >1 day benefit for patients receiving docetaxel and plinabulin compared to patients not receiving plinabulin.
• Plinabulin is given on the same day as chemotherapy as a short infusion, has minimal associated bone pain, no reduction in platelet count.
• In an separate analysis of breast cancer patients, plinabulin monotherapy was superior vs no treatment for docetaxel-induced neutropenia, the company said.

For further details see: